BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28331056)

  • 21. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
    Pagani IS; Dang P; Saunders VA; Grose R; Shanmuganathan N; Kok CH; Carne L; Rwodzi Z; Watts S; McLean J; Braley J; Altamura H; Yeung DT; Branford S; Yong ASM; White DL; Hughes TP; Ross DM
    Leukemia; 2020 Apr; 34(4):1052-1061. PubMed ID: 31768016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH; Li H; Cai H
    Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.
    van der Veer A; Zaliova M; Mottadelli F; De Lorenzo P; Te Kronnie G; Harrison CJ; Cavé H; Trka J; Saha V; Schrappe M; Pieters R; Biondi A; Valsecchi MG; Stanulla M; den Boer ML; Cazzaniga G
    Blood; 2014 Mar; 123(11):1691-8. PubMed ID: 24366361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interphase FISH for BCR-ABL1 rearrangement on neutrophils: A decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1 positive acute lymphoblastic leukemia.
    Balducci E; Loosveld M; Rahal I; Boudjarane J; Alazard E; Missirian C; Lafage-Pochitaloff M; Michel G; Zattara H
    Hematol Oncol; 2018 Feb; 36(1):344-348. PubMed ID: 28444777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
    DeBoer R; Koval G; Mulkey F; Wetzler M; Devine S; Marcucci G; Stone RM; Larson RA; Bloomfield CD; Geyer S; Mullighan CG; Stock W
    Leuk Lymphoma; 2016 Oct; 57(10):2298-306. PubMed ID: 26892479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia.
    Krumbholz M; Karl M; Tauer JT; Thiede C; Rascher W; Suttorp M; Metzler M
    Genes Chromosomes Cancer; 2012 Nov; 51(11):1045-53. PubMed ID: 22887688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
    Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
    J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
    Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
    Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
    Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
    BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
    Bastian L; Beder T; Barz MJ; Bendig S; Bartsch L; Walter W; Wolgast N; Brändl B; Rohrandt C; Hansen BT; Hartmann AM; Iben K; Das Gupta D; Denker M; Zimmermann J; Wittig M; Chitadze G; Neumann M; Schneller F; Fiedler W; Steffen B; Stelljes M; Faul C; Schwartz S; Müller FJ; Cario G; Harder L; Haferlach C; Pfeifer H; Gökbuget N; Brüggemann M; Baldus CD
    Blood; 2024 Apr; 143(14):1391-1398. PubMed ID: 38153913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IKZF1 deletion and co-occurrence with other aberrations in a child with chronic myeloid leukemia progressing to acute lymphoblastic leukemia.
    Klumb CE; Barbosa TDC; Nestal de Moraes G; Schramm MT; Emerenciano M; Maia RC
    Pediatr Blood Cancer; 2019 Apr; 66(4):e27570. PubMed ID: 30511400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Philadelphia chromosome in leukemogenesis.
    Kang ZJ; Liu YF; Xu LZ; Long ZJ; Huang D; Yang Y; Liu B; Feng JX; Pan YJ; Yan JS; Liu Q
    Chin J Cancer; 2016 May; 35():48. PubMed ID: 27233483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
    Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
    Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
    Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
    Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
    Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.